Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose oral semaglutide dose-ranging and efficacy trial in type 2 diabetes
2012-004994-16Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2013
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Jul 2013; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-004994-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004994-16.